AstraZeneca (NASDAQ: AZN ) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investmen ...

NEW YORK, Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=124344&from=4 CLASS PERIOD: February 23, 2022 to ...

LOS ANGELES, Jan. 23, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws.Shareholders who bought the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025. DJS Law Group CASE DETAILS: According to the complaint, AstraZeneca allegedly made false and ...

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”) ...

AZN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! ...

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), have until Friday, February 21, 2025 to seek appointment as lead plaintiff of the AstraZeneca class action lawsuit. Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZeneca class action lawsuit charges AstraZeneca and ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...

AstraZeneca (AZN) announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway.Post the FDA’s approval, the ADC drug is approved to treat unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy.This appro ...

Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class Action - AZN ...

Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN ...